T. Rowe Price
T. Rowe Price is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at T. Rowe Price.
T. Rowe Price is a company.
Key people at T. Rowe Price.
Key people at T. Rowe Price.
T. Rowe Price is an independent global investment management firm dedicated to helping clients achieve long-term financial goals through active management across equity, fixed income, multi-asset, and alternatives strategies.[1][2][4] Its mission centers on client success via integrity, intellectual rigor, and stability, with a philosophy of strategic investing—rigorous research, prudent risk management, and a future-focused approach to deliver consistent performance.[1][2][4] The firm manages $1.79 trillion in assets as of October 31, 2025, serving corporations, retirement plans, endowments, intermediaries, and sovereign entities in over 50 countries, with institutional clients comprising over 50% of AUM; it employs 938 investment professionals and over 7,800 associates worldwide.[1][5][6] Key sectors span emerging markets, government bonds, investment grade, high yield, retirement offerings, and specialized strategies like health sciences and the blue economy.[1][4]
In the startup ecosystem, T. Rowe Price influences growth through early-stage investments, such as in health sciences at human trial or concept stages, funding medical innovation with long-term societal impact; its active approach and global reach support emerging opportunities in tech and non-tech sectors.[4][6]
Founded in 1937 by Thomas Rowe Price, Jr., T. Rowe Price pioneered growth stock investing and a fee-based model, distinguishing it from commission-driven peers during its early years.[3][4] Price, a visionary investor, emphasized long-term value amid market cycles, laying the foundation for an independent firm guided by enduring principles.[1][3]
The firm evolved from a U.S.-focused growth equity manager to a global powerhouse, expanding into fixed income, multi-asset strategies, and alternatives while launching its first European fund and establishing offices across continents; today, it champions deliberate innovation in areas like retirement solutions, active ETFs, and thematic investing.[1][2][4]
T. Rowe Price rides trends like AI-driven growth and non-tech sector expansion, providing clear-eyed risk assessment amid market turbulence.[4][5] Its timing leverages decades of cycle navigation, positioning it to capitalize on evolving demands for active management in retirement, healthcare innovation, and global equities/bonds.[1][2][6] Favorable forces include rising institutional AUM (over 50%), demand for rigorous research in volatile environments, and innovation in ETFs and alternatives.[1][4][5] The firm shapes the ecosystem by funding early-stage breakthroughs (e.g., medical trials) and delivering insights via podcasts and reports, influencing advisors and investors on portfolio tactics amid AI and economic shifts.[4][5][6]
T. Rowe Price is poised to expand AUM through AI opportunities and non-tech diversification, emphasizing active strategies amid 2026 market risks.[4][5] Trends like retirement innovation, health sciences funding, and global volatility will shape its path, with its independent model enabling agile responses. Its influence may grow via deeper tech-health intersections and ETF adoption, solidifying its role as a client-first partner in an evolving financial world—echoing its 1937 founding focus on long-term thriving.[1][4]
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 4, 2026 | Third Arc Bio | $52.0M Series A | Andreessen Horowitz | AbbVie, Aberdeen Investments, Alderline Group, Biotechnology Value Fund, Galapagos, Goldman Sachs Alternatives, Hillhouse Investment, Marshall Wace, Omega Funds |
| Feb 2, 2026 | Waymo | $16.0B Series D | Alphabet, Dragoneer Investment Group, DST Global, Sequoia Capital | Andreessen Horowitz, BDT & MSD Partners, Bessemer Venture Partners, CapitalG, Fidelity, Google Ventures, Kleiner Perkins, Mubadala Capital, Perry Creek Capital, Silver Lake, Temasek Holdings, Tiger Global Management |
| Jan 28, 2026 | Cellares | $257.0M Series D | BlackRock, Eclipse Ventures | Baillie Gifford, Decheng Capital, DFJ Growth, Duquesne Family Office, EDBI, Gates Frontier Fund, Intuitive Ventures, Willett Advisors LLC |
